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STRICTLY SPEAKING ABOUT EPHEDRA: A BASEBALL
TRAGEDY HELPING TO DEFINE THE DYNAMIC BETWEEN
WARNING DEFECT AND DESIGN DEFECT
I. INTRODUCTION
On August 17, 2003, Kiley Bechler spread the ashes of her re-
cently deceased husband, Steve Bechler, on the pitcher's mound at
Camden Yards.1 This solemn gesture marked an end to one chap-
ter of the tragic saga that began with the twenty-three year-old
pitcher's unexpected death.
2
Just several months earlier, Steve Bechler reported to the Balti-
more Orioles spring training camp ten pounds overweight.
3 To
lose weight for the upcoming baseball season, Bechler took an over-
the-counter dietary supplement called Xenadrine RFA-1
("Xenadrine"), which contains ephedra. 4 Bechler reportedly took
three Xenadrine capsules each morning, one capsule over the rec-
ommended dosage printed on the bottle. 5 On Friday, February 14,
1. See Thomas Loverro, Bechler has an eternal presence at Camden, WASH. TIMES,
Aug. 18, 2003, at C1 (describing how Kiley Bechler spread her husband's ashes on
Camden Yards' main pitcher's mound and two other pitching mounds located in
ballpark's bullpen after Sunday's Baltimore Orioles-New York Yankees game).
2. See id. ("'I think this is where he would want to be,' Kiley Bechler said. 'It
adds a little closure to everything that has been going on and brings a little bit of
joy to a pretty sad situation."').
3. See Gary Washburn, Ephedrine cited in Bechler's death, at http://baltimore.ori-
oles.mlb.com/NASApp/mlb/bal/news/bal-news.jsp?ymd=20030226&content-id=
204807&vkey=spt2003news&fext=.jsp (Feb. 26, 2003) (explaining Bechler's physi-
cal condition was not as it was in past seasons). Bechler was listed at 239 pounds
and reported to spring training weighing approximately 249 pounds. See id.
4. See id. (discussing how Xenadrine is used for weight-loss by increasing me-
tabolism speed and heart rate). Xenadrine is manufactured by both Cytodyne
Technologies and Phoenix Laboratories. See id.; see also Ex parte Gen. Nutrition
Corp., 855 So. 2d 475, 478 (Ala. 2003) (describing how woman's use of Xenadrine,
which contains ephedra, may have contributed to her sudden cardiac death).
While Steve Bechler was taking Xenadrine with ephedra, it must be noted that an
ephedra-free version of the dietary supplement Xenadrine-EFX ("EFX") was on
the market and available for consumption. See Issues Relating to Ephedra-containing
Dietary Supplements: Hearings Before the Subcomm. on Oversight and Investigations of the
House Comm. on Energy and Commerce, 108th Cong. (2003) [hereinafter Hearings]
(prepared statement of Robert Chinery) (describing how Cytodyne Technologies
launched ephedra-free Xenadrine-EFX in early 2002), available at http://energy
commerce.house.gov/108/Hearings/07232003hearingl021/Chineryl640.htm.
For a further discussion of ephedra, see infra notes 23-27 and accompanying text.
5. See Murray Chass, Pitcher's Autopsy Lists Ephedra as One Factor, N.Y. TIMES,
Mar. 14, 2003, at D5 (stating Xenadrine's recommended dosage as two tablets per
morning and two tablets per afternoon).
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2003, Bechler reported to training camp and passed a routine phys-
ical examination. 6 Later that day, Bechler completed the Orioles'
first day of drills at spring training without incident.7 Two days
later, however, Steve Bechler suddenly collapsed on the practice
field from heat exhaustion.8
Orioles' trainers examined the twenty-three year-old pitcher at
the training facility, but were unable to help him.9 Bechler was
rushed to the hospital where his temperature reached a staggering
108 degrees, causing his body to overheat, leading to "cell death"
and ultimately multiple system organ failure.1 0 At 10:10 a.m., on
Monday, February 17, 2003, Steve Bechler died.1
Bechler's autopsy revealed that ephedra was a significant factor
in the pitcher's death. 12 Later investigation revealed that Bechler
suffered from a history of abnormal liver functions and mild hyper-
tension prior to the day of his collapse. 13
6. See Becky Dubin Jenkins, Physician explains Bechler's death, at http://balti-
more.orioles.mlb.com/NASApp/mlb/bal/news/bal-news.jsp?ymd=20030217&
content id=201272&vkey=spt2003news&fext=.jsp (Feb. 17, 2003) ("Bechler did
not report any problems to the doctor who examined him and was deemed 'fit to
go' and 'fit to play.' Bechler did have a routine EKG in 1999, and it, too, was
normal.").
7. See Becky Dubin Jenkins, O's Notes: Bechler taken to hospital, at http://balti-
more.orioles.mlb.com/NASApp/mlb/bal/news/bal-newsjsp?ymd=20030216&
content id=200789&vkey=spt2003news&fext=.jsp (Feb. 16, 2003) (discussing how
Orioles' manager, Mike Hardgrove, commented that Bechler finished Friday's first
day drills, but he finished them tired). The very next day, Saturday, Bechler fin-
ished most of the team drills, but was taken out of practice for disciplinary reasons.
See id.
8. See id. (describing Bechler's participation in running drills before he
collapsed).
9. See id. (running through various events taking place during thirty-seven
minute time period from when trainers brought Bechler to Orioles' training room
at 11:35 a.m. until emergency personnel transported Bechler from field at 12:12
p.m.).
10. SeeJenkins, supra note 6 (explaining Bechler's multiple organ failure was
due to heatstroke).
11. See id. (describing events surrounding Bechler's death at North Ridge
Medical Center in Fort Lauderdale, Florida). "Bechler's pregnant wife, Kiley, was
at his bedside when he died." Id.
12. See Chass, supra note 5, at D5 (attributing Bechler's death, in part, to
ephedra found in his system). "Releasing the toxicology report, Dr.Joshua Perper,
the Broward County medical examiner, said, 'It is my professional opinion that the
toxicity of ephedra played a significant role in the death of Mr. Bechler, although
it's impossible to define mathematically the contribution of each one of the factors
in his unfortunate death due to heatstroke."' Id. Dr. Perper revealed his findings
during a press conference and in a detailed thirteen page report on Bechler's
death. See id.
13. See id. (explaining how interviews and previous medical examinations re-
vealed other risk factors which may have contributed to Bechler's death).
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In response to her husband's death, Kiley Bechler sued the
makers of Xenadrine in a Florida federal court.14 She is asking for
600 million dollars in a products liability lawsuit for wrongful
death. 15 The complaint sets forth six claims against the
defendants. 16
This Comment focuses on two of Kiley Bechler's strict products
liability claims, specifically design defect and warning defect. 17 By
addressing the circumstances surrounding Steve Bechler's death,
this Comment explains the relationship between a product's warn-
ing and its design in a strict products liability lawsuit.18 Section II
provides a general background of Florida strict products liability
law for design defect and warning defect.19 Section III applies Flor-
ida law to the facts surrounding Steve Bechler's death.20 Section IV
discusses certain practical considerations concerning Bechler's case
and the policy-driven ramifications of Florida's stance on strict
products liability law. 2 1 Section IV also highlights new develop-
14. See Peter Schmuck, Bechler's widow sues companies for $600M; Lawsuit alleges
ephedra killed Orioles pitcher, BALT. SUN, July 18, 2003, at DI (stating Kiley Bechler
filed her lawsuit in United States District Court in Fort Lauderdale). Kiley Bechler
filed her lawsuit against Cytodyne Technologies, Phoenix Laboratories, and
Cytodyne president Robert Chinery on Wednesday, July 16, 2003. See id. The law-
suit also named an unidentified company which sold the dietary supplement to
Steve Bechler. See id.
15. See id. (alleging defendants disregarded safety of consumers in order to
bolster profits).
16. See Complaint of Kiley Bechler at 11-16, Kiley Bechler v. Cytodyne Techs.,
Inc. (S.D. Fla. July 16, 2003) (No. 03-61369) [hereinafter Complaint] (claiming neg-
ligence, breach of express warranty, breach of implied warranty, and three counts
of strict liability for inherently, unreasonably dangerous product, failure to warn,
and misrepresentations).
17. For a discussion of design defect, see infra notes 47-86 and accompanying
text. For a discussion of warning defect, see infra notes 87-115 and accompanying
text.
18. For a discussion of the relationship between warning defect and design
defect, see infra notes 156-74 and accompanying text.
19. For a discussion of pertinent Florida strict products design defect case
law, see infra notes 47-86 and accompanying text. For a discussion of pertinent
Florida strict products warning defect case law, see infra notes 87-115 and accom-
panying text.
20. For a discussion of the application of the consumer expectations test to
the circumstances surrounding Steve Bechler's death, see infra notes 119-32 and
accompanying text. For a discussion of the application of the risk-utility test to the
circumstances surrounding Steve Bechler's death, see infra notes 133-44 and ac-
companying text.
21. For a discussion of Florida's policy-driven view of strict products liability
law, see infra notes 179-86 and accompanying text.
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ments, including recent FDA action, and the grim future of
ephedra. 22
II. BACKGROUND
A. The Attack on Ephedra
Ephedra, also known as ma huang, is a natural substance de-
rived from plants. 23 In China, ephedra has been used for
thousands of years to treat various respiratory ailments.24 Today,
the plant is crushed and formulated into pills, teas, and other
forms, and sold as dietary supplements.25 Dietary supplements are
promoted by the industry as diet aids, muscle builders, and energy
boosters.26 These claims, however, have never been substantiated. 27
The federal government, through the Dietary Supplement and
Health Education Act of 1994 ("DSHEA"), does not require manu-
facturers of dietary supplements to prove product safety or effec-
tiveness before placing them on the market.28 Instead, before a
dietary supplement can be removed from the market, the Federal
Drug Administration ("FDA") must prove that the supplement
is unsafe.2 9 Under this regulatory system, dangerous products,
22. For a discussion of current events regarding ephedra, see infra notes 187-
95 and accompanying text.
23. See The Origins, Uses and Risks of a Supplement, N.Y. TIMES, Dec. 31, 2003, at
A14 [hereinafter Supplement] (explaining origins of ephedra). "Ephedra is defined
as '1. Any of various gymnospermous, mostly shrubby plants of the genus Ephedra,
some of which are used as a source of ephedrine. 2. A stimulant, often sold as pills
or tablets, derived from a plant of this genus."' Ex parte Gen. Nutrition Corp., 855
So. 2d 475, 478 n.2 (Ala. 2003) (quoting AMERIcAN HERITAGE DICTIONARY OF THE
ENGLISH LANGUAGE (4th ed., Houghton Mifflin Co. 2000)).
24. See Supplement, supra note 23, at A14 (describing origins and medical uses
of ephedra in China). "Ephedra contains two alkaloids, ephedrine and
pseudoephidrine. These compounds can combat congestion and ease breathing
in some conditions." Id.
25. See id. (finding some form of ephedra in nearly 200 different dietary sup-
plements). All of these supplements were sold without a prescription. See id.
26. See id. ("Manufacturers and retailers have claimed the herb is good for
weight control, building muscle and boosting energy.").
27. See Mark B. McClellan, Remark of the Commissioner of Food and Drugs, 58
FooD & DRUG LJ. 191, 200 (2003) (describing how manufacturers of ephedra
products make unsubstantiated claims about enhancing athletic performance).
28. See Lauren J. Sloane, Comment, Herbal Garden of Good and Evil: The Ongo-
ing Struggles of Dietaiy Supplement Regulation, 51 ADMIN L. REV. 323, 326-27 (1999)
(defining obligations of FDA when regulating dietary supplements); see also Don-
ald G. McNeil, Jr., Sometimes, the Labels Lie, N.Y. TIMES, Sept. 9, 2003, at F7 (discuss-
ing dietary supplement manufacturers do not have to prove their products work).
"That's how products like ephedra end up on shelves and in magazine advertise-
ments before it's discovered that they can kill people." Id.
29. See Sloane, supra note 28, at 326 (showing difficulties with regulating diet-
ary supplements after imposition of DSHEA).
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like ephedra, are pulled off the shelves only after the damage is
done.3 0
The eighteen billion dollar-per-year dietary supplement indus-
try has recently come under attack because of its deceptive market-
ing practices. 31 In fact, Cytodyne Technologies, Inc., the makers of
Xenadrine, recently lost a 12.5 million dollar lawsuit for false adver-
tising practices.3 2 In addition, the commissioner of the FDA has
publicly professed that the agency is chasing down the makers of
ephedra products for their "unsubstantiated claims. '33
The FDA is not alone; plaintiffs nationwide are attacking the
manufacturers of dietary supplements containing ephedra, claim-
ing their products are unsafe and should be removed from the mar-
ket immediately. 34 For instance, the family of a woman who
recently died while exercising on a high school track sued the mak-
ers of Xenadrine for her unexpected death. 35 In addition, Kelci
Stringer, the widow of former Minnesota Vikings pro-bowler Korey
Stringer, has made accusations that ephedra contributed to her
30. See Winnie Hu, Albany Leaders Reach Accord On Ephedra Ban, N.Y. TIMES,
June 11, 2003, at B6 (stating New York state legislators agreed to ban ephedra sales
statewide). With approval from Governor Pataki, New York would join Illinois as
only the second state banning over-the-counter sales of ephedra after Steve
Bechler's death. See id. "The Food and Drug Administration has reported 123
deaths associated with ephedra since 1993. Dietary supplements, unlike drugs, do
not need the agency's approval before going on the market." Id.
31. See Ford Fessenden, Studies of Dietary Supplements Come Under Growing Scru-
tiny, N.Y. TIMES, June 23, 2003, at Al (explaining how industry research is less than
scientific and frequently misleading to consumers).
32. See id. (describing how makers of ephedra and other dietary supplements
misuse data in scientific studies). "Cytodyne ... exaggerated the findings of
clinical trials it commissioned, Superior Court Judge Ronald L. Styn said in ruling
on a class action suit, but [Cytodyne] had also cajoled some researchers into fudg-
ing results in published scientific articles." Id.; see also Ephedra: Cytodyne to Pay $12.5
Million in 'Xenadrine' case, at http://www.legalnewswatch.com/news_208.html (May
30, 2003) (describing both sides' reactions to court's decision).
33. See McClellan, supra note 27, at 200 (discussing need for stronger warning
labels on any ephedra products still marketed). The commissioner stated: "We are
also executing a series of actions against ephedra products making unsubstantiated
claims, for example about sports performance enhancement, and against manufac-
turers that in effect are marketing alternatives to street drugs." Id.
34. See Register, Big Class Action, at http://www.bigclassaction.com/classac-
tion/ephedra2.html (last visited Nov. 14, 2004) (indicating first nationwide class
action against leading ephedra makers was filed). Plaintiffs to this class action law-
suit are seeking monetary compensation for injuries and death, reimbursement of
payments made for ephedra containing products, a recall of all dietary supple-
ments containing ephedra, a medical monitoring fund, and a public statement by
the makers of ephedra regarding the dangers of their products. See id.
35. See Ex parte Gen. Nutrition Corp., 855 So. 2d 475, 478 (Ala. 2003) ("The
autopsy report stated, among other things, that 'her death is consistent with a sud-
den cardiac death."'). The woman allegedly purchased the Xenadrine at a local
General Nutrition Center ("GNC") retail store in Newport News, Virginia. See id.
5
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husband's heat stroke and death in 2001.36 Kiley Bechler is leading
the attack on the ephedra industry through her 600 million dollar
lawsuit, and her weapon of choice is strict products liability.3 7
B. Strict Products Liability38
In West v. Caterpillar Tractor Co.,3 9 the Florida Supreme Court
adopted the doctrine of strict liability as set out in the Restatement
(Second) of Torts Section 402A.40 A manufacturer will be held
strictly liable if the plaintiff proves that: "(1) a product (2) pro-
duced by a manufacturer (3) was defective or created an unreason-
ably dangerous condition (4) that proximately caused (5) injury. '41
A plaintiff does not need to prove that a manufacturer was negli-
gent to succeed in a strict products liability action. 42 The policy
36. See Chris Williams, Vikings raise ephedra as 'causal link' to Stringer's fatal heat-
stroke, USA TODAY.COM, Feb. 25, 2003 (commenting on Kelci Stringer's 100 million
dollar wrongful death lawsuit against Vikings), available at http://www.usatoday.
com/sports/football/nfl/vikings/2003-02-25-stringer-ephedrax.htm. Ripped
Fuel, a dietary supplement containing ephedra, was found in Stringer's locker on
the day of his death. See id. The examining doctors did not find any direct evi-
dence that Stringer took Ripped Fuel on the morning of his death. See id. The
National Football League banned ephedra after Stringer's death. See id.
37. See Complaint, supra note 16, at 11-14 (detailing Kiley Bechler's strict liabil-
ity claims).
38. This Comment focuses on Florida tort law because the federal court
hearing Kiley Bechler's lawsuit will apply Florida law. For further discussion on the
application of Florida law, see supra note 14 and accompanying text.
39. 336 So. 2d 80 (Fla. 1976).
40. See id. at 87 (indicating Florida followed trend of numerous states by
adopting doctrine of strict liability); see also RESTATEMENT (SECOND) OF TORTS
§ 402A (1965). Section 402A provides:
(1) One who sells any product in a defective condition unreasonably
dangerous to the user or consumer or to his property is subject to
liability for physical harm thereby caused to the ultimate user or con-
sumer, or to his property, if
(a) the seller is engaged in the business of selling such a product,
and
(b) it is expected to and does reach the user or consumer without
substantial change in the condition in which it is sold.
(2) The rule stated in Subsection (1) applies although
(a) the seller has exercised all possible care in the preparation and
sale of his product, and
(b) the user or consumer has not brought the product from or en-
tered into any contractual relation with the seller.
Id.
41. Edward M. Chadbourne, Inc. v. Vaughn, 491 So. 2d 551, 553 (Fla. 1986)
(finding insufficient proof of proximate cause, and therefore, manufacturer could
not be held strictly liable). If the plaintiff proves all five points, the manufacturer
of the defective product is strictly liable. See id.
42. See Ferayorni v. Hyundai Motor Co., 711 So. 2d 1167, 1170-71 (Fla. Dist.
Ct. App. 1998) (noting Florida strict products liability law does not require negli-
gence). "In fact [manufacturers] can be found liable even though [they were]
6
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surrounding strict products liability is premised on the manufac-
turer's ability to better bear the costs of injuries resulting from de-
fective products. 43
In a products liability action based on strict liability, a product
is considered defective if it is in a condition unreasonably danger-
ous to the consumer.44 The three theories used when considering
a product's defectiveness are design defect, manufacturing defect,
and warning defect.45 Because this Comment focuses on the rela-
tionship between design defect and warning defect, manufacturing
defect will not be discussed.46
1. Design Defect
When determining whether a product is defectively designed, a
court may choose between two tests. 47 Under Florida law, trial
courts are given wide discretion to use either the consumer expec-
tation test or the risk-utility test.4 8 In some instances, Florida courts
have even applied both tests concurrently. 49 As a result, all litigants
utterly non-negligent." Id. at 1171 (quoting Moorman v. Am. Safety Equip., 594
So. 2d 795, 800 (Fla. Dist. Ct. App. 1992)).
43. See Cassisi v. Maytag Co., 396 So. 2d 1140, 1150 (Fla. Dist. Ct. App. 1981)
("[T]he purpose of strict liability is to ensure that the costs of injuries resulting
from defective products be borne by their makers who put them into the channels
of trade rather than by injured persons who ordinarily are powerless to protect
themselves."); see also West, 336 So. 2d at 92 (stating similar rationale for holding
manufacturers liable for defective products).
44. See Cassisi, 396 So. 2d at 1143-44 (stating products are not required to be
both defective and unreasonably dangerous). "On first impression, the [Second]
Restatement may seem to require proof that the product be both defective and
unreasonably dangerous. That, however, is not the case [in Florida]." Id. at 1143.
45. SeeJennings v. BIC Corp., 181 F.3d 1250, 1255 (11th Cir. 1999) (applying
Florida law); see also Ferayorni, 711 So. 2d at 1170 (noting three distinct theories
that define defective products).
46. For a discussion of the relationship between warning defect and design
defect, see infra notes 156-74 and accompanying text.
47. See Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264, 271 (Fla.
2000) (stating two tests for design defect are consumer expectation and risk-utility
tests).
48. See id. at 272 (stating either test is acceptable, or even both); see also Spen-
cer H. Silverglate, The Restatement (Third) of Torts: Product Liability-The Tension Be-
tween Product Design and Product Warnings, 75 FLA. B.J. 10, 14 (2001) (describing
confusion that exists with Florida's standard jury instructions in design defect
cases). "In contrast, the Third Restatement adopts the risk-utility balancing test to
determine design defect [, however,] . . .consumer expectations ... may be con-
sidered as part of the risk-utility balancing test." Id.
49. See Taylor v. Gen. Motors Corp., 875 F.2d 816, 818-19 (11th Cir. 1989)
(recognizing two theories of strict liability for design defect and applying both
tests); see also Zimmer, Inc. v. Birnbaum, 758 So. 2d 714, 715 (Fla. Dist. Ct. App.
2000) (asserting validity of instructingjury on both theories).
7
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in design defect cases must be keenly aware of the ramifications of
both tests in design defect claims.50
a. Consumer Expectation Test
The consumer expectation test provides that "[a] product is
unreasonably dangerous because of its design if the product fails to
perform as safely as an ordinary consumer would expect when used
as intended or in a manner reasonably foreseeable by the manufac-
turer. "51 While the consumer expectation test is easily applied to
manufacturing defect claims, the test is generally more difficult to
apply to design defect claims.52
In Jennings v. BIC Corp.,53 a three year-old boy accidentally lit
his brother's pajamas on fire with a BIC lighter. 54 The boys'
mother sued BIC for her son's personal injuries. 55 Her lawsuit al-
leged BIC's failure to provide a child proof feature rendered the
lighter defective in design. 56 The case was to be tried before ajury
in the United States District Court for the Middle District of Flor-
50. See Zimmer, 758 So. 2d at 715 (describing how appellate review may be
precluded in cases where both consumer expectation test and risk-utility test were
used injury's general verdict). In Zimmer, the plaintiff was precluded from appeal-
ing his case because the court could not decipher which test the jury applied in
coming to its verdict. See id. The plaintiff claimed that the trial court erred when
instructing the jury on the consumer expectation test. See id. Affirming the jury's
ruling for the defendant, the court stated:
The jury charge gave the jury two standards for determining whether the
product was unreasonably dangerous - the ordinary consumer test and
the risk benefit test. Zimmer concedes that the risk benefit test was ap-
propriate to use in this case. The verdict form did not require the jury to
identify its basis for deciding that the product was defective. Zimmer did
not object at trial to the use of the verdict form. The jury might properly
have decided that the rods were defective based on a risk benefit analysis.
Even if we found error in the definition of the ordinary consumer test or
in its submission to the jury, under the two issue rule, Zimmer is unable
to demonstrate prejudice to justify a reversal.
Id. An attorney should make a timely objection when he or she is faced with a
general verdict, and the jury has been instructed on both the consumer expecta-
tion test and the risk-utility test. See id.
51. Standard Jury Instructions, 778 So. 2d at 271 (setting forth specific jury in-
struction for consumer expectation test).
52. See Cassisi v. Maytag Co., 396 So. 2d 1140, 1145 (Fla. Dist. Ct. App. 1981)
(describing difficulties in applying consumer expectation test to design defect and
warning defect claims).
53. 181 F.3d 1250 (l1th Cir. 1999).
54. See id. at 1253 (observing lighter did not have child-proof feature).
55. See id. (stating mother's response to son's injury).
56. See id. (alleging design defect because lighter was unreasonably danger-
ous). The lawsuit also alleged that 7-Eleven was liable for selling the defective
lighter and the store that sold the flammable pajamas was liable for distributing
flammable pajamas. See id.
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ida.5 7 The court, however, granted BIC's motion for summary judg-
ment and Jennings' case was dismissed. 58 Jennings appealed the
district court's summary judgment.59 She contended the court
erred in finding that BIC had no duty to child-proof its lighters.
60
The issue on appeal was "limited to whether the alleged design de-
fect of the lighter, i.e., its lack of childproof features, render[ed] it
unreasonably dangerous." 61
Florida courts utilize both the consumer expectation test and
the risk-utility test to decide whether a product is unreasonably dan-
gerous.62 In Jennings, the court focused on the consumer expecta-
tion test.63 Both tests require the jury to use an objective standard
to determine whether the product is defective. 64 Using the con-
sumer expectation objective standard, the court judged the defec-
tiveness of the lighter from an ordinary consumer's standpoint,
rather than from an ordinary three year-old child's standpoint.
65
As a matter of law, the court held that lighters lacking child-proof
features are not defective. 66
57. See id. at 1253 (discussing procedural history).
58. SeeJennings, 181 F.3d at 1253 (explaining facts and procedural history).
Originally, the lawsuit was filed in Florida state court, but the defendant removed
it to federal court. See id. While the court granted BIC's motion for summary
judgment, the jury rendered verdicts in favor of the other defendants. See id. at
1253-54.
59. See id. at 1254 ("Jennings appeals the trial court's grant of summary judg-
ment to BIC, its denial of leave to amend, and its evidentiary rulings. Jennings also
appeals the jury verdict on the ground that the trial court gave erroneous
instructions.").
60. See id. (arguing BIC should have designed lighter with child-proof
features).
61. Id. at 1255 (emphasis in original) (determining design defectiveness by
using objective standards, not subjective standards).
62. See Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264, 271 (Fla.
2000) (articulating Florida Supreme Court's jury instructions for strict liability, de-
sign defect). "A product is unreasonably dangerous because of its design if [the
product fails to perform as safely as an ordinary consumer would expect when used
as intended or in a manner reasonably foreseeable by the manufacturer] [or] [the
risk of danger in the design outweighs the benefits]." Id. (alterations in original).
The jury instructions for design defect give Florida courts flexibility to define "un-
reasonably dangerous" by using the consumer expectation test, the risk-utility test,
or both. See id. at 272. The Florida Supreme Court does not prefer either test. See
id. Therefore, trial courts must determine what test is appropriate on a case-by-
case basis. See id.
63. SeeJennings, 181 F.3d at 1255 (applying consumer expectation test).
64. See id. (differentiating between two tests). "The consumer expectation
test requires consideration of the ordinary consumer's expectations." Id.
65. See id. (finding lighter could be defective by three year-old child's subjec-
tive standard).
66. See id. at 1255-56 (declaring neither consumer expectation test or risk-
utility test use subjective "child's-perspective standard" to find defectiveness); see
also Standard Jury Instructions, 778 So. 2d at 271 (using ordinary consumer standard
9
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In a vigorous dissent, Judge Barkett posited that the case
should be sent to the Florida Supreme Court for clarification on
the existing state of Florida strict products liability law, specifically
design defect. 67 The dissent suggested a jury could find BIC light-
ers without child-proof features defective in design under the objec-
tive ordinary consumer standard. 68  This objective standard
requires contemplating the "consideration of the ordinary con-
sumer's expectations."69 Ordinary consumer expectations reasona-
bly include the expectation of young children playing with
lighters. 70 The dissent asserted that "in light of the high casualty
rate and the obviousness of the danger, a jury could well find BIC
lighters to be defectively designed under an objective, ordinary con-
sumer standard."71
Furthermore, the majority in Jennings limited a manufacturer's
liability to situations where a product is used only as intended. 72
The Florida standard jury instruction for the consumer expectation
test allows ajury to find a defendant liable when a product is used
in a foreseeable manner or as intended. 73 By limiting liability to
for consumer expectation test). The ultimate burden of persuasion is on the
plaintiff to prove the manufacturer's product is unreasonably dangerous. See id. at
272.
67. SeeJennings, 181 F.3d at 1260 (Barkett,J., dissenting) (explaining there is
no binding precedent on point to support majority's holding).
68. See id. at 1261 (agreeing with majority that objective analysis was proper).
69. See id. at 1260 (considering "normal public expectation of danger" is an-
other way to phrase ordinary consumer expectations). The dissent believed that
the majority was erroneous in finding that the "normal public expectation of dan-
ger" of lighters did not include the probability that children could set fires. See id.
at 1261.
70. See id. at 1260-61 (noting majority puts forth evidence of apparent dangers
involved when children play with lighters). The dissent stated:
However, given that, by the majority's own admission, "140 people, in-
cluding 125 children, are killed each year in fires caused by children play-
ing with lighters," it is hard to credit the conclusion that the "normal
public expectation of danger" would not include the risk of fires so
caused, and that expectation of such a risk would arise only if one
adopted "a subjective, child's-perspective standard."
Id. (citations omitted).
71. Id. at 1261 (arguing summary judgment in favor of BIC was
inappropriate).
72. SeeJennings, 181 F.3d at 1261 (BarkettJ., dissenting) (stating majority mis-
interpreted previous precedent set forth in High v. Westinghouse Elec. Corp., 610
So. 2d 1259 (Fla. 1992)). "The majority posits that a 'manufacturer is [strictly]
liable only when the product is used as intended,' and asserts, on the basis of High,
that a child's use of a cigarette lighter to set fire to things that are not intended to
be burned is an unintended use under Florida law." Id. at 1261 (alterations in
original).
73. See Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264, 271 (Fla.
2000) (allowing jury to find liability for any foreseeable use or intended use of
products).
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only intended uses, the majority excluded any reasonably foresee-
able use, or misuse, as a basis to find BIC liable for design defect.
74
Accordingly, had the majority in Jennings applied the reasonably
foreseeable use standard, it may have reached a different result.
75
The reasonably foreseeable use standard will ultimately play a role
in Bechler's case. 76
b. Risk-Utility Test
Florida courts also apply the risk-utility test to decide whether a
product is defectively designed. 77 The risk-utility test requires bal-
ancing the utility of the product against the risk it creates. 78 If a
product's risk outweighs its utility, then the product's design is de-
fective. 79 When applying the risk-utility test, courts find Professor
Wade's seven factors helpful.80
74. See Jennings, 181 F.3d at 1261 (Barkett, J., dissenting) (concluding that
High provides no support for majority's finding that "manufacturers are not strictly
liable for injuries caused by reasonably foreseeable uses of their products").
75. See id. (predicting different result if majority had applied reasonable
foreseeabilty standard).
76. See Standard Jury Instructions, 778 So. 2d at 271 (noting foreseeable use, or
misuse, will not preclude jury from entering verdict for plaintiff). For a discussion
of Steve Bechler's foreseeable misuse, see infra notes 128-32 and accompanying
text.
77. See Radiation Tech., Inc. v. Ware Constr. Co., 445 So. 2d 329, 331 (Fla.
1983) (applying risk-utility test to determine whether product was unreasonably
dangerous); see also RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 2 re-
porter's note, cmt. d, § 11(B) (1998) (stating Florida law does not explicitly require
proof of alternative design in design defect cases, however, it may be implicit that
proof of alternative design is needed to prove design defect).
78. See RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 2 reporter's
note, cmt. d, § II(B) (1998) (discussing importance of reasonable alternative de-
sign in design defect cases where risk-utility test is applied). "Under risk-utility
balancing the likelihood and magnitude of foreseeable harm is balanced against
the burden of precaution against the anticipated harm." Id.
79. See id. (explaining risk-utility test).
80. See Sperry-New Holland v. Prestage, 617 So. 2d 248, 256 (Miss. 1993) (rec-
ommending trial courts apply Professor Wade's seven factors). Professor Wade's
seven factors are:
(1) The usefulness and desirability of the product - its utility to the user
and to the public as a whole.
(2) The safety aspects of the product - the likelihood that it will cause
injury, and the probable seriousness of the injury.
(3) The availability of a substitute product which would meet the same
need and not be as unsafe.
(4) The manufacturer's ability to eliminate the unsafe character of the
product without impairing its usefulness or making it too expensive to
maintain its utility.
(5) The user's ability to avoid danger by the exercise of care in the use of
the product.
(6) The user's anticipated awareness of the dangers inherent in the prod-
uct and their avoidability, because of general public knowledge of the
11
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The risk-utility test is another way to determine whether a
product design is unreasonably dangerous to consumers.
8
' Over
the last decade, the national judicial trend has been to apply the
risk-utility test instead of the consumer expectation test.8
2 Courts
have recognized that the risk-utility test provides a useful balance,
protecting both consumers and manufacturers.
8 3
While the risk-utility test is separate and distinct from the con-
sumer expectation test, the risk-utility test may encompass some
consumer expectations in its balancing approach.
4 For instance,
in design defect claims, the risk-utility test may allow for consumer
expectations to be balanced against the gravity of harm that could
result from the product, the availability of a safer design, and the
economic feasibility of a safer design.
85 Inevitably, certain con-
sumer expectations will creep into the risk-utility balancing
formula.8 6
obvious condition of the product, or of the existence of suitable warnings
or instructions.
(7) The feasibility, on the part of the manufacturer, of spreading the loss
by setting the price of the product or carrying liability insurance.
Id. at 256 n.3 (quoting John W. Wade, On the Nature of Strict Tort Liability for Prod-
ucts, 44 Miss. L.J. 825, 837 (1973)).
81. See Radiation Tech., 445 So. 2d at 331 (applying risk-utility test and not
consumer expectation test to determine design defect). The Supreme Court of
Florida stated:
The term "unreasonably dangerous" more accurately depicts liability of a
manufacturer or supplier in that it balances the likelihood and gravity of
potential injury against the utility of the product, the availability of other,
safer products to meet the same need, the obviousness of the danger,
public knowledge and expectation of the danger, the adequacy of instruc-
tions and warnings on safe use, and the ability to eliminate or minimize
the danger without seriously impairing the product or making it unduly
expensive.
Id.
82. See Speny-New Holland, 617 So. 2d at 255 (recognizing risk-utility test "has
become the trend in most federal and state jurisdictions").
83. See id. at 256 (pointing out consumers and manufacturers benefit from
courts applying risk-utility test).
84. See Cassisi v. Maytag Co., 396 So. 2d 1140, 1144-45 (Fla. Dist. Ct. App.
1981) (mentioning isk-utility balancing approach may include consumer expecta-
tions of product utility).
85. See id. at 114546 (explaining burden shift to defendant to prove product's
design is not defective). The court holds:
Once the plaintiff establishes a prima facie case showing that his injuries
were caused by the product's design, the burden is shifted to the defen-
dant to prove the design was not defective by presenting evidence of fac-
tors, such as gravity of the danger posed by the challenged design, the
feasibility of a safer design, the financial cost of the improved design, etc.
Id. (emphasis in original).
86. See Wade, supra note 80, at 837 (accounting for certain factors in risk util-
ity analysis that are similar to consumer expectations). Wade's sixth factor ac-
counted for "[tlhe user's anticipated awareness of the dangers inherent in the12
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2. Warning Defect
The Supreme Court of Florida has not explicitly adopted a
standard jury instruction for strict liability failure to warn. 87 In fact,
the court chose not to develop a standard jury instruction.88 It de-
cided to await "further development of Florida law" before taking a
specific position on strict liability failure to warn. 89 Therefore, Flor-
ida courts are free to adopt their own jury instructions for claims of
strict liability warning defect, which has created considerable confu-
sion throughout the legal community. 90
In Ferayorni v. Hyundai Motor Co.,91 a seventeen year-old girl was
killed in a car accident.92 She was driving a 1990 Hyundai Excel
equipped with an automatic shoulder belt and a manual lap belt.
93
At the time of impact, the decedent was not properly utilizing the
vehicle's restraint system.94 Specifically, she was not wearing the lap
belt and she improperly placed the shoulder harness under her
arm, not over her shoulder.95 The improperly placed shoulder har-
product and their avoidability, because of general public knowledge of the obvious
condition of the product .... " Id. For a discussion of Professor Wade's seven
factors, see supra note 80 and accompanying text.
87. See Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264, 271-72
(Fla. 2000) (declining to adopt standard jury instruction for strict liability failure to
warn). There are, however, standard jury instructions for strict liability design de-
fect and manufacturing defect. See id. at 271.
88. Id. at 272 (describing explicitly that Florida does not have standard jury
instruction for strict liability warning defect). Because Florida does not have a
uniform jury instruction, the lower courts are free to come up with their own jury
instructions for strict liability failure to warn. See id.
89. Id. (noting Supreme Court of Florida is awaiting further developments in
Florida law before creating standard jury instruction for warning defect). The
court is offering a flexible approach until an adequate standard jury instruction is
adopted. See id.
90. See Michael Flynn, The Healthy Debate: A Proposal for the Addition of Negligent
Failure to Warn and Strict Liability Failure to Warn Jury Instructions to the florida Stan-
dard Jury Instructions for Product Liability Cases, 25 NOVA L. REv. 267, 268 (2000)
(finding confusion among attorneys and judges throughout Florida's legal com-
munity). "Absent this guidance from the supreme court, trial lawyers and trial
judges scramble to put together jury instructions of which neither the lawyers, nor
the judges, can be confident will hold up on appeal." Id. Flynn describes this as a
needless debate. See id.
91. 711 So. 2d 1167 (Fla. Dist. Ct. App. 1998).
92. See id. at 1169 (mentioning decedent's car was struck by another vehicle).
93. See id. (describing Hyundai Excel's restraint system). "A 'manual' seatbelt
must be applied by the occupant, while a 'passive' seatbelt is one which automati-
cally moves into place around the occupant." Id. at 1169 n.1.
94. See id. at 1169 (noting improper use of seatbelt).
95. See id. (illustrating decedent's misuse of vehicle's restraint system). 13
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ness caused internal injuries, which were the undisputed cause of
her death. 9 6
Ferayorni's estate sued Hyundai for failing to warn of the risk
associated with improper use of the seatbelt.97 At trial, the jury
found for the defendant Hyundai. 98 The estate appealed, claiming
the trial court improperly instructed the jury on the strict liability
failure to warn claim.99 On appeal, the court remanded the case
for a new trial only on this claim. 100 In doing so, the court clarified
strict liability failure to warn law in Florida. 10 1
Traditionally, the negligence of a manufacturer was irrelevant
when dealing with strict products liability claims; "[h]owever, a
claim of strict liability arising specifically from a failure to warn may
be an exception to the generally recognized distinction between
negligence and strict liability."1 02 Courts have struggled over
whether proof of manufacturers' knowledge of their products' dan-
gerous tendencies should be a consideration in strict liability failure
to warn claims. 103
In Ferayorni, the court employed a hybrid approach. 1 04 It main-
tained the knowledge requirement to support a claim of strict liabil-
ity for failure to warn. 10 5 The court, however, did not go as far as
equating strict liability failure to warn with negligent failure to
96. Ferayorni, 711 So. 2d at 1169 (deeming decedent's death to be direct result
of her internal injuries).
97. See id. ("The estate's theory of the case was that Hyundai was aware that
smaller drivers experience 'neck-cutting' from the shoulder harness and respond
by wearing the shoulder harness under their arms.").
98. See id. (noting estate's complaint included claims of design defect and
inadequate warning).
99. See id. (stating Ferayorni's alleged improperjury instructions were given to
jury at trial).
100. See id. at 1173 (declaring trial court incorrectly failed to instruct jury on
strict liability failure to warn).
101. See Ferayorni, 711 So. 2d at 1173 (instructing lower court to apply jury
instructions for strict liability failure to warn).
102. Id. at 1171; see also West v. Caterpillar Tractor Co., 336 So. 2d 80, 90 (Fla.
1976) ("Strict liability means negligence as a matter of law or negligence per se,
the effect of which is to remove the burden from the user of proving specific acts
of negligence.").
103. See Ferayomi, 711 So. 2d at 1170 (deciding whether to incorporate negli-
gence principles into strict liability failure to warn claims). "The issue, specifically,
is whether a claim of strict liability failure to warn requires, like its counterpart in
negligence, proof that the manufacturer knew or should have known of the prod-
uct's dangerous propensities." Id. at 1171.
104. See id. at 1172 (deciding to adopt neither negligence based nor pure
strict liability approach in failure to warn claims).
105. See id. (finding it unnecessary to completely dispose of actual knowledge
or constructive knowledge requirements in strict liability failure to warn claims).
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warn. 11°6 By following the Supreme Court of California's decision in
Anderson v. Owens-Coming Fiberglass Corp.,'07 the Ferayorni court
seemed to find a middle ground.
10 8
In Anderson, the Supreme Court of California reasoned that
completely eliminating the knowledge requirement would turn
strict liability failure to warn into absolute liability.109 Strict liability
failure to warn "require[s] a plaintiff to prove only that the defen-
dant did not adequately warn of a particular risk that was known or
knowable in light of the generally recognized and prevailing best sci-
entific and medical knowledge available at the time of manufacture
and distribution."'110 Therefore, the reasonableness of a manufac-
turer's failure to warn is irrelevant in a strict products liability fail-
ure to warn case. I1 '
After Ferayorni, Florida courts recognized that "manufacturers
are not required to warn of every risk which might be remotely sug-
gested by any obscure tidbit of available knowledge, but only of
those risks which are discoverable in light of the 'generally recognized
and prevailing best' knowledge available."' 2 Aside from knowability,
manufacturers have a duty to warn about the dangers associated
with their products when these hazards are not obvious or well
known to consumers. 1 3 If a warning is required, the adequacy of
the warning is usually a question left to the jury. 1 4 Nevertheless,
when a warning is "'accurate, clear and unambiguous"' ajudge may
decide the warning is adequate as a matter of law."
5
106. See id. (holding strict liability failure to warn claims do not require prov-
ing negligence).
107. 810 P.2d 549 (Cal. 1991).
108. See Ferayorni, 711 So. 2d at 1172 (claiming correct balance was established
in Anderson).
109. See Anderson, 810 P.2d at 552 (finding absolute liability contrary to public
policy). If manufacturers were held liable for unknowable dangers, they would be
discouraged from developing new products for fear of liability. See id. at 556.
110. Id. at 558 (emphasis added).
111. See id. at 558-59 (describing main difference between strict liability fail-
ure to warn and negligent failure to warn).
112. Ferayorni, 711 So. 2d at 1172 (quoting Anderson, 810 P.2d at 558) (empha-
sis in original) (recognizing strict liability failure to warn standard is higher thresh-
old to meet when compared to negligent failure to warn). Yet, the court did not
go as far as making manufacturers the insurers of their products. See id.
113. See Thursby v. Reynolds Metals Co., 466 So. 2d 245, 251 (Fla. Dist. Ct.
App. 1984) (explaining when manufacturers have duty to warn).
114. See Ragans v. Miriam Collins-Palm Beach Labs. Co., 681 So. 2d 1173,
1174 (Fla. Dist. Ct. App. 1996) (discussing whose duty it is to decide adequacy of
product's warning).
115. See id. (quoting Felix v. Hoffmann-LaRoche, Inc., 540 So. 2d 102, 105
(Fla. 1989)) (observing general requirements for adequate warnings).
15
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III. ANALYSIS
A. Application of Design Defect Tests
For Kiley Bechler's design defect claim to prevail, she must
prove Xenadrine fails either the consumer expectation test or the
risk-utility test 16 Both tests play a significant role in assessing
whether Xenadrine's design is defective because Florida courts do
not specify a preference for either test.117 This Section highlights
the critical aspects of design defect litigation by applying each test
to the facts surrounding Steve Bechler's death." t8
1. Application of the Consumer Expectation Test
A product fails the consumer expectation test when it "fails to
perform as safely as an ordinary consumer would expect when used
as intended or in a manner reasonably foreseeable by the manufac-
turer."'19  Steve Bechler was an ordinary consumer, taking
Xenadrine to lose excess weight. 20 Kiley Bechler can argue that
Xenadrine failed to perform as safely as an ordinary consumer
would expect because ordinary consumers typically expect to lose
weight from taking Xenadrine; they do not expect to develop seri-
ous health problems or ultimately die.' 21
Cytodyne, the manufacturer of Xenadrine, might argue that
Steve Bechler was an unintended user because he suffered from
abnormal liver functions and mild hypertension prior to taking
116. For a discussion of tests courts may apply to prove a design defect, see
supra notes 47-86 and accompanying text.
117. See Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264, 271(Fla. 2000) (describing how trial courts may apply both tests).
118. For a discussion of the application of the consumer expectation test, see
infra notes 119-32 and accompanying text. For a discussion of the application of
the risk-utility test, see infra notes 133-44 and accompanying text.
119. Standard Jury Instructions-Civil Cases, 778 So. 2d at 271 (indicating properjury instruction for consumer expectation test).
120. See Washburn, supra note 3 (recounting Bechler's reason for taking
Xenadrine).
121. See Complementary and Alternative Medicine: Study calls for major reforms in
marketing of ephedra, HEART DISEASE WKLv., Sept. 7, 2003, at 17 (on file with author)(claiming marketers have made "misleading statements about the safety, use, and
efficacy" of ephedra supplements). A study found forty-one percent of websites
marketing ephedra did not disclose the adverse effects or contraindications relat-
ing to supplement use. See id. Fifty-three percent of the websites marketing
ephedra did not describe the proper dosage. See id. Thirty-four percent of the
websites marketing ephedra contained misleading statements "which could result
in serious harm to consumers" taking ephedra. Id. "Many of the web-sites in this
study contained advertisements claiming no adverse side effects from the dietary
supplement." Id.
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Xenadrine.122 Cytodyne may assert this defense by utilizing the ma-
jority's reasoning in Jennings.123 In Jennings, the court found that
cigarette lighters "are not to be used as children's playthings" and
held that a child was an unintended user of a lighter.1 24 The major-
ity found the child to be an unintended user primarily because the
packaging warned consumers to keep the lighter away from chil-
dren.125 Because the child in Jennings was an unintended user, the
court held that the lighter was not defective in design. 126 Like the
child in Jennings, Bechler may be considered an unintended user
because he suffered from contraindications listed on the Xenadrine
label.127
Even though Cytodyne has a strong argument that Steve
Bechler was an unintended user, this fact alone does not foreclose
the possibility that Xenadrine is defectively designed. 128 Kiley
Bechler could argue the dissent's position in Jennings.129 She can
claim that her husband was a foreseeable user, or misuser, of
Xenadrine. 130 Steve Bechler used Xenadrine in a manner inconsis-
tent with the label because he exceeded the manufacturer's recom-
122. See Chass, supra note 5, at D5 (describing how Bechler suffered from
ailments that may have contributed to his death); see also Did Xenadrine Kill Balti-
more Orioles' Steve Bechler?, at http://ultimatefatburner.com/xenadfine-steve-
bechler.html (last visited Nov. 15, 2004) (explaining Bechler suffered from contra-
indicated symptoms). Bechler not only suffered from contraindicated symptoms,
he also exceeded the recommended dosage. See id. "[Steve Bechler] was not a
candidate for safe ephedra use. Simply put, Mr. Bechler should never have used
Xenadrine." Id. (emphasis in original).
123. SeeJennings v. BIC Corp., 181 F.3d 1250, 1256 (11th Cir. 1999) (finding
no design defect because of unintended use). For a discussion of the Jennings
majority opinion, see supra notes 53-66 and accompanying text.
124. Jennings, 181 F.3d at 1256 (describing children playing with lighters as
unintended users of lighters). "[L]ighters are intended to be used to set fire to
things that are intended to be burned: cigarettes, cigars, candles, etc." Id.
125. See id. (stating warning on package said to "'[k]eep out of reach of
children"').
126. See id. (illustrating unintended users may be barred from claiming strict
liability design defect).
127. For a discussion of unintended users, see supra notes 72-76 and accompa-
nying text.
128. See Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264, 271
(Fla. 2000) (allowing foreseeable use or misuse in strict products liability claim of
design defect). "A product is unreasonably dangerous because of its design if [the
product fails to perform as safely as an ordinary consumer would expect used as
intended or in a manner reasonably foreseeable by the manufacturer] . Id. (emphasis
added).
129. SeeJennings, 181 F.3d at 1261 (Barkett, J., dissenting) (maintaining fore-
seeable use is distinct from unintended use).
130. See Standard Jury Instructions-Civil Cases, 778 So. 2d at 271 (leaving option
available to argue foreseeable use or misuse when product is not used as
intended). 17
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mended dosage and suffered from hypertension and liver
problems.13 ' Nevertheless, Bechler's use of Xenadrine may have
been "reasonably foreseeable by the manufacturer," and the prod-
uct could still be found unreasonably dangerous, and therefore, de-
fective in design. 13 2
2. Application of the Risk-Utility Test
Xenadrine would fail the risk-utility test if "the risk of danger in
the design outweighs the benefits" of the dietary supplement. 133 In
Florida, a reasonable alternative design is not explicitly required to
prove a design defect; however, it is a very important factor in per-
suading the jury.1 34 Xenadrine-EFX, the ephedra-free version of
Xenadrine, could be a reasonable alternative design to
Xenadrine.135  In fact, the President of Cytodyne Technologies
touted Xenadrine-EFX as a "better-ephedra free product" when
comparing it to Xenadrine, which contains ephedra. 13 6 This evi-
dence suggests that an alternative design was available to Cytodyne
at the time of Bechler's death. 13 7
131. See Chass, supra note 5, at D5 (describing Steve Bechler's use of
Xenadrine as inconsistent with product's label).
132. See generally Standard Jury Instructions-Civil Cases, 778 So. 2d at 272 (noting
plaintiff has burden of persuasion).
133. Id. at 271 (describing proper way to apply risk-utility analysis). The
plaintiff will put forth evidence to support the proposition that the risks of
Xenadrine outweigh the benefits of Xenadrine. See id. The defendant will put
forth evidence that Xenadrine's benefits outweigh any risks or dangers associated
with the product. See id.
134. See Radiation Tech., Inc. v. Ware Constr. Co., 445 So. 2d 329, 331 (Fla.
1983) (illustrating how Supreme Court of Florida finds reasonable alternative de-
sign important factor when applying risk-utility test).
The term "unreasonably dangerous" more accurately depicts liability of a
manufacturer or supplier in that it balances the likelihood and gravity of
potential injury against the utility of the product, the availability of other,
safer products to meet the same need, the obviousness of the danger, public knowl-
edge and expectation of the danger, the adequacy of instructions and warnings on
safe use, and the ability to eliminate or minimize the danger without seriously
impairing the product or making it unduly expensive.
Id. (emphasis added).
135. See Hearings, supra note 4 (indicating Xenadrine-EFX was available in
early 2002).
136. See id. (maintaining Cytodyne's position regarding safety and efficacy of
Xenadrine). In his prepared witness testimony to the House Committee on En-
ergy and Commerce, Cytodyne Technologies President Robert Chinery acknowl-
edged that he thought Xenadrine-EFX was a "better-ephedra free product." See id.
Chinery also noted that Cytodyne Technologies began phasing out advertising and
promotion of Xenadrine in early 2002, and they completely stopped selling
Xenadrine in early 2003 - coincidentally, just a short while after Steve Bechler's
death. See id.
137. See id. (admitting better alternative to Xenadrine existed at time of
Bechler's death).
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When analyzing the utility of Xenadrine under a risk-utility bal-
ancing test, the "usefulness and desirability" of the product must be
assessed. 138 Obesity in the United States is a growing concern.
139
Every year, more and more Americans are categorized as over-
weight or obese.140 Combating obesity is of the utmost importance
in maintaining an individual's health, and a safe and effective diet-
ary supplement is undoubtedly a useful product.1
41
If the court performs a risk-utility test it will consider other fac-
tors as well. 142 These factors include: the serious nature of Steve
Bechler's injury, the availability of alternative dietary supplements,
Cytodyne's ability to eliminate the ephedra found in Xenadrine
while maintaining the utility of its product, Bechler's ability to avoid
the dangerous propensities of Xenadrine by properly using the
product, and Bechler's awareness of the dangers associated with di-
etary supplements containing ephedra.1 43 All of these factors will
play a role in determining Cytodyne's liability under the risk-utility
test. 144
138. SeeWade, supra note 80, at 837 (depicting importance of product's utility
in balancing approach). Professor Wade's first factor in assessing defectiveness is:
"The usefulness and desirability of the product - its utility to the user and to the
public as a whole." Id.
139. See Obesity, Diabetes on the Increase in US, at http://usgovinfo.about.com/
library/weekly/aa010803a.htm (last visited Nov. 15, 2004) (listing obesity among
top health concerns in United States). "Obesity and diabetes are among our top
public health problems . . . ." Id.
140. See Defining Overweight and Obesity, at http://www.cdc.gov/nccdphp/
dnpa/obesity/defining.htm#Adults (last visited Nov. 15, 2004) (stating statistics for
obese and overweight Americans). "Results of the National Health and Nutrition
Examination Survey (NHANES) 1999-2000 indicate that an estimated 64 percent
of U.S. adults are either overweight or obese, defined as having a body mass index
(BMI) of 25 or more." Id.; see also Obesity Trends, at http://www.cdc.gov/nccdphp/
dnpa/obesity/trend/prevschar.htm (last visited Nov. 15, 2004) (finding recent
obesity trends across America). "In 2000, 38.8 million American adults met the
classification of obesity, defined as having a body mass index, BMI score of 30 or
more. Between 2000 and 2001 obesity prevalence climbed from 19.8 percent of
American adults to 20.9 percent of American adults." Id.
141. See Hearings, supra note 4 (stating Cytodyne has received responses from
thousands of people who have "lost weight and have improved their quality of
life").
142. See Wade, supra note 80, at 837 (describing factors used when evaluating
defective and unreasonably dangerous products).
143. See id. (illustrating seven factors used in risk-utility analysis). For a discus-
sion of Professor Wade's seven factors, see supra note 80 and accompanying text.
144. See Wade, supra note 80, at 837 (noting factors may be used when assess-
ing potential liability).
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B. Application of the Warning Defect Test
Under strict liability failure to warn, a product may be defective
because of an inadequate warning.1 45 Manufacturers and sellers
may not avoid liability simply by placing warnings on their prod-
ucts. 146 The warning "should contain some wording directed to the
significant dangers arising from failure to use the product in the
prescribed manner, such as the risk of serious injury or death. 1 47
If a warning does not convey the actual risk associated with the use
of the product, the warning is inadequate and that product is
defective. 148
Xenadrine's warning label did not communicate that death or
serious injury could result from taking the dietary supplement. 149
The label did, however, suggest consulting a physician or licensed
health care professional if the user suffered from an assortment of
ailments. 150 Steve Bechler did not heed this suggestion, as he did
not consult a health care professional before using Xenadrine.1 5 1
An adequate warning must make the danger of a product ap-
parent to the consumer. 152  Kiley Bechler could argue that
Xenadrine's warning label did not convey a sufficiently forceful
message that would adequately warn a reasonable person of the
145. See Ferayorni v. Hyundai Motor Co., 711 So. 2d 1167, 1170 (Fla. Dist. Ct.
App. 1998) (observing products may still be rendered defective if warning is inade-
quate). "[A] product may be defective by virtue of a design defect, a manufactur-
ing defect, or an inadequate warning." Id.
146. See Flynn, supra note 90, at 269 ("[T]he mere existence of a warning is
not dispositive of the adequacy of the warning.").
147. Brown v. Glade & Grove Supply, Inc., 647 So. 2d 1033, 1036 (Fla. Dist.
Ct. App. 1994) (describing how inadequate wording may render product defec-
tive). "The mere existence of warnings ... is not dispositive of the adequacy of the
warning for several reasons. A warning may be defective not only by virtue of inad-
equate warning, but as a result of its location and the manner in which the warning
is conveyed." Id. at 1035.
148. See Flynn, supra note 90, at 269-70 (noting both manufacturer and seller
may be liable).
149. See Gary Mihoces, USA TODAY.COM, Ephedrine under baseball's micro-
scope, at http://www.usatoday.com/sports/baseball/2003-02-20-cover-ephedrine-
baseball x.htm (Feb. 20, 2003) (explaining contents of Xenadrine's warning).
150. See id. (describing warning on Xenadrine bottle). Xenadrine's warning
label reads: "'Consult a physician or licensed health professional before using this
product if you are at risk of, have a family history of, or are being treated for'
assorted conditions, including high blood pressure (hypertension) and liver
problems." Id.
151. See Chass, supra note 5, at D5 (noting Bechler had abnormal liver func-
tions and mild hypertension prior to taking Xenadrine).
152. See Am. Cyanamid Co. v. Roy, 466 So. 2d 1079, 1082 (Fla. Dist. Ct. App.
1984) (stating -product's warning label should clarify any dangerous conse-
quences). "To warn adequately, the product must make apparent the potential
harmful consequences." Id.
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product's serious dangers. 153 If the wording of Xenadrine's warn-
ing label was not sufficiently frightening, then the warning may be
deemed inadequate and the product defective. 154 Ultimately, the
issue of adequacy is reserved for the finder of fact.
155
C. The Relationship Between Warning Defect and
Design Defect
Distinguishing a design defect from a warning defect is critical
when assessing a manufacturer's potential liability in a strict prod-
ucts liability lawsuit.156 These two areas of strict products liability
law frequently overlap and require manufacturers to strike a bal-
ance between a product's design and warning. 157 Therefore, a
153. See id. ("The warning should be of such intensity as to cause a reasonable
man to exercise for his own safety caution commensurate with the potential
danger.").
154. See id. (describing failure to give adequate warning may result in award-
ing punitive damages); see also Hildy Bowbeer et al., Warning! Failure to Read this
Article May Be Hazardous to Your Failure to Warn Defense, 27 WM. MITCHELL L. REv.
439, 453 (2000) (noting adequate warnings clearly describe potential dangers to
consumers).
155. See Bowbeer, supra note 154, at 453 ("Ordinarily, the question of whether
a given warning is adequate is left to the finder of fact."). One may find James
Sales' seven factors helpful when determining the adequacy of a warning. See id.
These factors provide:
First, a warning must be conspicuous. It must be printed in such a man-
ner as to assure that a user's attention will be attracted to its message.
Second, it should use symbols when appropriate. For example, a skull
and crossbones device may be necessary in addition to written warnings if
the product can cause death. Third, it must sufficiently communicate the
risk of danger associated with the product. In that regard, the warning
must be qualitatively sufficient to impart the particular risk of harm.
Fourth, the warning must be located where the user is likely to encounter
it. In some cases, placement of the warning in an owner's manual or
package insert will be sufficient; in others, placement on the product it-
self may be required. In the latter case, the warning must be placed
where it will catch the user's eye. Fifth, the warning must be clear and
unambiguous. Its content must not be vague or otherwise minimize the
likelihood of the very harm it is seeking to put the user on guard of.
Sixth, the warning must be sufficiently broad and encompassing and not
unduly limited in scope. If the product can reasonably be put to a num-
ber of uses, the warning should address each. Seventh, the warning must
be undiluted. That is, the manufacturer cannot engage in marketing or
promotional activities, which tend to negate the very dangers the warning
speaks of.
Id. at 453-54 (footnotes omitted).
156. See, e.g., Silverglate, supra note 48, at 14 (explaining relationship between
product warnings and product design).
157. See id. (balancing need for product warnings and product design under
Florida law).
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court's application of the law plays a significant role in assessing a
manufacturer's or seller's liability for defective products. 158
In 1976, Florida adopted strict liability as set forth by the Re-
statement (Second) of Torts section 402A.159 "Since then, Florida
[strict] products liability law has proceeded in anything but a
straight line." 160 To provide some clarity, Florida courts have
adopted specific jury instructions for strict product liability claims
of design defect and manufacturing defect.161 The courts, however,
have not provided standard jury instructions for strict liability duty
to warn, which has created considerable confusion. 162
Striking the proper balance between the manufacturer's obli-
gation to design safe products and holding consumers responsible
for adhering to product warnings is a problem that has been ad-
dressed in other jurisdictions. 163 In Delaney v. Deere & CO., 1 6 4 the
Kansas Supreme Court considered that adequate warnings do not
always save a product from being defective in design. 165 While ana-
lyzing the effects of placing an adequate warning on a product that
158. See id. at 14-16 (describing results in cases where product designs and
product warnings are balanced to assess defectiveness).
159. See West v. Caterpillar Tractor Co., 336 So. 2d 80, 87 (Fla. 1976) (follow-
ing trend of states adopting § 402A). For a further discussion of West, see supra
notes 3940 and accompanying text.
160. Silverglate, supra note 48, at 14. "Even today, considerable confusion
and disagreement exist in Florida as to the present state of products liability law."
Id.
161. See Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264, 272
(Fla. 2000) (listing applicable jury instructions for strict products claims); see also
Flynn, supra note 90, at 272 (positing Florida should provide standard jury instruc-
tions on strict liability duty to warn).
162. See Flynn, supra note 90, at 267-68 (indicating need for standard jury
instructions for strict liability failure to warn claims). "Absent this guidance from
the supreme court, trial lawyers and trial judges scramble to put together jury in-
structions of which neither lawyers, nor the judges, can be confident will hold up
on appeal." Id. at 268.
163. See Silverglate, supra note 48, at 12 (highlighting case law that describes
relationship of product warnings to design defect).
164. 999 P.2d 930 (Kan. 2000).
165. See id. at 946 (holding "an adequate warning does not foreclose a finding
that a product is defectively designed"). The court in Delaney clearly stated the
issue as:
Does Kansas follow the portion of Comment j of the Restatement (Sec-
ond) of Torts § 402A, which provides that a product bearing an adequate
warning is not in defective condition, or instead, would Kansas now adopt
Comment I of the Restatement (Third) of Torts § 2, which provides that
an adequate warning does not foreclose a finding that a product is defec-
tively designed?
Id. at 940.
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could have been better designed, the court in Delaney described the
conflicting positions of the Second and Third Restatements. a66
Commentj of the Restatement (Second) of Torts section 402A
provides that "a product bearing an adequate warning is not in [a]
defective condition."1 67 On the other hand, comment 1 of the Re-
statement (Third) of Torts section 2 "provides that an adequate
warning does not foreclose a finding that a product is defectively
designed."1 68 In Delaney, the court declined to adopt either Restate-
ment's interpretation of the effect of an adequate warning on a de-
sign defect and instead chose to adopt its own view. 169 The Kansas
Supreme Court held that an adequate warning does not foreclose
finding a product defective in design; however, the court did not
flatly adopt comment I of the Third Restatement either.170
Florida courts have not explicitly stated their position on
whether an adequate warning precludes a claim for design de-
fect.1 71 Their reluctance in adopting a steadfast view has been de-
scribed as establishing "a reasonable balance between the
manufacturer's obligation to design safe products and its right to
have its warnings and instructions heeded." 172 By not clearly re-
jecting or accepting either commentj of Restatement (Second) of
166. See id. at 940 (deciding whether Kansas follows commentj of Restate-
ment (Second) of Torts § 402A or comment I of Restatement (Third) of Torts
§ 2).
167. Id. (explaining Second Restatement's view on warnings). "Where warn-
ing is given, the seller may reasonably assume that it will be read and heeded; and
a product bearing such a warning, which is safe for use if it is followed, is not in
defective condition, nor is it unreasonably dangerous." RESTATEMENT (SECOND) OF
TORTS § 402A cmt. j (1965).
168. Delaney, 999 P.2d at 940 (interpreting Third Restatement's view). The
Third Restatement provides:
Relationship between design and instruction or warning. Reasonable designs
and instructions or warnings both play important roles in the production
and distribution of reasonably safe products. In general, when a safer
design can reasonably be implemented and risks can reasonably be de-
signed out of a product, adoption of the safer design is required over a
warning that leaves a significant residuum of such risks.
RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 2 cmt. 1 (1997) (emphasis
in original).
169. See Delaney, 999 P.2d at 946 (choosing not to adopt either Restatements'
position).
170. See id. (refusing to adopt Third Restatement's point of view and holding
adequate warnings do not preclude design defect claims).
171. See Silverglate, supra note 48, at 14 (maintaining Florida law "has pro-
ceeded in anything but a straight line" since adopting strict products liability doc-
trine in West); see also Standard Jury Instructions-Civil Cases (99-1), 778 So. 2d 264,
272 (Fla. 2000) (declining to give instruction on strict liability failure to warn
claims).
172. Silverglate, supra note 48, at 14 (claiming Florida law provides appropri-
ate balance between manufacturer and consumer rights).
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Torts section 402A or comment 1 of Restatement (Third) of Torts
section 2, Florida is taking a Delaney-like approach to strict product
liability claims by combining warning and design defect.173 This
case-by-case approach will have a direct impact on the court's assess-
ment of Kiley Becheler's claims against Cytodyne Technologies. 174
IV. CONCLUSION
Dietary supplements containing ephedra are a danger for cer-
tain people, namely athletes.1 75 Individuals suffering from any one
of fourteen ailments listed on the warning label should not take
Xenadrine.1 76 Steve Bechler suffered from two such ailments,
which rendered him an unfit candidate to take Xenadrine. 77 On
the other hand, Xenadrine's warning label did not indicate the seri-
ous risks associated with product misuse.178
The tragic events surrounding Steve Bechler's death highlight
a murky area of Florida strict products liability law. 179 For example,
if the warning label on the bottle of Xenadrine is defective, then
173. See generally Delaney, 999 P.2d at 940-46 (rejecting rigid approach that
products with adequate warnings are immune from claims of design
defectiveness).
174. See Silverglate, supra note 48, at 14-16 (analyzing various Florida cases
where adequate warnings precluded defective design claims).
175. See Metabolife Int'l, Inc. v. Wornick, 264 F.3d 832, 852 (9th Cir. 2001)
(claiming over 800 Adverse Event Reports were associated with ephedrine-based
products in 1997). "In 1997, for example, the FDA proposed a rule establishing a
dosage regimen and labeling requirements for dietary supplements containing
ephedrine alkaloids such as ma haung." Id. The proposed rule was in response to
known serious health risks, such as stroke and death. See id. See generally Proceed
With Caution: How Safe Is Weight Loss Supplement Xenadrine?, ABC NEWS.coM, at
http://abcnews.go.com/sections/GMA/GoodMorningAmerica/GMA01 1121
Xenadrinerisks.html (last visited Sept. 24, 2004) [hereinafter Proceed With Cau-
tion] (highlighting dangers of Xenadrine). Since 1994, the FDA has received over
1,400 complaints of health problems associated with dietary supplements contain-
ing ephedra. See id. These consumer complaints included high blood pressure,
strokes, and heart attacks. See id.
176. See Proceed With Caution, supra note 175 (listing fourteen ailments that
preclude Xenadrine use). The fourteen ailments include: "high blood pressure,
liver problems, thyroid problems, diabetes, pernicious anemia, nervousness, anxi-
ety, depression, seizure disorder, cardiac arrhythmias, stroke, pheochromocytoma,
prostate enlargement and psychiatric disease." Id. The Xenadrine label also cau-
tions "not to exceed the recommended dosages." Id.
177. See Chass, supra note 5, at D5 (noting Bechler suffered from abnormal
liver functions and mild hypertension).
178. See generally id. (noting warning does not explicitly mention that death
could result from taking Xenadrine). Dietary supplements containing ephedra
have been advertised as natural and safe products. See id.
179. See Silverglate, supra note 48, at 17 (finding Florida law unclear). For a
discussion of the unsettled areas of Florida Strict Liability failure to warn, see supra
notes 159-62 and accompanying text.
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Cytodyne Technologies will be held strictly liable.180 If the label is
adequate, the warning is not defective, and the court's application
of the consumer expectation and the risk-utility tests take center
stage. 18
1
Precedent highlights the difficulties of finding a product defec-
tive in design after establishing that an adequate warning existed on
the product.182 The current approach of the Florida courts, while
somewhat complex, is a flexible and reasonable alternative. 183 The
hard-line approach of the Third Restatement, emphasizing product
design over the use of warnings, seems harsh to manufacturers.
1 8 4
On the other hand, the Second Restatement's approach seems to
foreclose many legitimate consumer claims.18 5 By sitting on the
fence between the two Restatements, Florida appears to be striking
a reasonable balance for both plaintiffs and defendants in warning
and design defect cases. 186
After several high profile deaths, the FDA finally intervened
and began taking drastic measures to warn consumers of the dan-
gers associated with ephedra.'8 7 First, the FDA suggested that la-
bels of dietary supplements containing ephedra should warn
consumers about serious adverse reactions such as heart attacks,
seizures, strokes, and death.188 Next, on December 30, 2003, the
180. See generally Bowbeer, supra note 154, at 441 (indicating strict liability
failure to warn claims may find otherwise safe products defective).
181. See Brown v. Glade & Grove Supply, Inc., 647 So. 2d 1033, 1036 (Fla. Dist.
Ct. App. 1994) (indicating adequate warnings do not foreclose finding products
defective under design defect).
182. For a discussion of the difficulties the Jennings court had in finding de-
fectiveness, see supra notes 53-75 and accompanying text.
183. See Silverglate, supra note 48, at 17 (stating Florida courts should con-
tinue using "common sense approach").
184. See RESTATEMENT (THIRD) OF TORTS: PRODucTS LIABILITY § 2 cmt. 1
(1997) (emphasizing safer design requirements over mere warnings about danger-
ous attributes).
185. See RESTATEMENT (SECOND) OF TORTS § 402A cmt. j (1965) (foreclosing
design defect claim if adequate warning is present on product).
186. See Silverglate, supra note 48, at 17 (depicting reasonable balance in Flor-
ida's approach to balancing product design and product warning).
187. See Christopher Drew, Official Urges Ban Of Ephedra By Baseball, N.Y.
TIMES, July 25, 2003, at DI (reporting FDA commissioner urged major league base-
ball to ban ephedra). "The FDA has been scrutinizing dozens of deaths, including
some high school athletes, that might be linked to ephedra." Id. at D3. The FDA
reviewed more than 17,000 consumer complaints relating to ephedra-based dietary
supplements. See id.
188. See generally HHS Acts to Reduce Potential Risks of Dietary Supplements Con-
taining Ephedra, at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00875.html
(Feb. 28, 2003) (announcing series of actions aimed at protecting consumers from
dietary supplements containing ephedra). Based on new medical evidence, the
FDA became increasingly concerned about the implications of potentially serious
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FDA announced plans to prohibit the sale of dietary supplements
containing ephedra.18 9 Finally, on February 11, 2004, the FDA is-
sued a ruling that bans all dietary supplements containing
ephedra.190 In its ruling, the FDA publicly announced that dietary
supplements containing ephedra "present an unreasonable risk of
illness or injury." 191 This ruling became effective on April 12,
2004.192
The FDA's ruling sent shockwaves throughout the dietary sup-
plement industry, and companies like Cytodyne are heading for the
hills. 193 Cytodyne has already changed its name to Nutraquest and
health risks associated with ephedra-based dietary supplements. See id. The FDA
took a proactive approach by proposing a warning label for all ephedra-containing
dietary supplements. See id. The FDA noted:
The proposed label [for ephedra containing dietary supplements] warns
about the risks of serious adverse events, including heart attack, seizure,
stroke, and death; cautions that the risk can increase with the dose, with
strenuous exercise, and with other stimulants such as caffeine; specifies
certain groups (such as women who are pregnant or breast feeding) who
should never use these products; and lists other conditions, such as dis-
eases and the use of certain medications, that rule out the use of ephe-
drine alkaloids.
Id. As Kiley Bechler's argument goes, had Steve Bechler been informed of the
possibility that he could die from taking Xenadrine, he might still be alive today.
See Complaint, supra note 16, at 13 (stating warning label did not warn that use of
Xenadrine could lead to death). Kiley Bechler's complaint claims the warning was
inadequate because it failed to warn of the possibility of death. See id. "Nowhere
does it warn on the label that reducing food intake or engaging in exercise while
also consuming ephedra or Xenadrine RFA-1 can be harmful or even fatal; to the
contrary, the label encourages use of the product in conjunction with dieting and
exercise." Id. (emphasis in original).
189. See FDA Announces Plans to Prohibit Sales of Dietary Supplements Containing
Ephedra, at http://www.hhs.gov/news/press/2003pres/20031230.html (Dec. 30,
2003) (announcing FDA's plans to ban sales of dietary supplements containing
ephedra). The announcement placed companies on notice of the FDA's intent to
issue a final agency ruling. See id.
190. See Dietary Supplements that Present a Significant or Unreasonable Risk:
Dietary supplements containing ephedrine alkaloids, 21 C.F.R. § 119.1 (2004).
191. Id. Stating that:
Dietary supplements containing ephedrine alkaloids present an unrea-
sonable risk of illness or injury under the conditions of use recom-
mended or suggested in labeling, or if no conditions of use are suggested
or recommended in labeling, under ordinary conditions of use. There-
fore, dietary supplements containing ephedrine alkaloids are adultered
under section 402(f) (1) (A) of the Federal food, Drug, and Cosmetic Act.
Id.
192. See id. (stating date that final rule goes into effect).
193. See Michael O'Keeffe, QUEST FOR THE TRUTH: Lawsuits, creditors have
supplement company on the defensive, N.Y. DAILY NEWS, Nov. 3, 2003, at 62 (stating
recent developments in bankruptcy litigation have garnered media attention).
"Some fear Nutraquest filed for bankruptcy to duck courtjudgments, protect presi-
dent Bob Chinery's personal assets and thwart future lawsuits." Id.
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filed for chapter eleven bankruptcy protection. 194 Nevertheless,
both lawyers and creditors are chomping at the bit to get a piece of
the estimated 350 to 600 million dollars in Xenadrine proceeds
alone.1 95 In the meantime, with her case only in the pretrial litiga-
tion phase, Kiley Bechler waits for another painful chapter in her
life to come to a close.
Michael Kane
194. See id. (describing how Cytodyne sold Xenadrine to another company
and then changed its name to Nutraquest).
195. See id. (stating seventy lawsuits are currently pending against Cytodyne,
a.k.a. Nutraquest). Most of the pending lawsuits are products liability cases. See id.
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